1-[(2R,3R,4R,5S)-5-({[(S)-({[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-3-carbamoyl-4-[(1S)-2-oxocyclohexyl]-1$l^{5}-pyridin-1-ylium

• ChemBase编号: 2867
• 分子式: C27H35N7O15P2
• 平均质量: 759.552222
• 单一同位素质量: 759.16663672
• SMILES: NC(=O)c1c[n+](ccc1[C@@H]1CCCCC1=O)[C@@H]1O[C@@H](COP(=O)([O-])O[P@](=O)(O)OC[C@@H]2O[C@H]([C@H](O)[C@H]2O)n2cnc3c2ncnc3N)[C@H](O)[C@H]1O
• Canonical SMILES: O[C@H]1[C@H](COP(=O)(O[P@@](=O)(OC[C@@H]2O[C@H]([C@@H]([C@H]2O)O)n2cnc3c2ncnc3N)O)[O-])O[C@H]([C@@H]1O)[n+]1ccc(c(c1)C(=O)N)[C@@H]1CCCCC1=O
• InChI: InChI=1S/C27H35N7O15P2/c28-23-18-25(31-10-30-23)34(11-32-18)27-22(39)20(37)17(48-27)9-46-51(43,44)49-50(41,42)45-8-16-19(36)21(38)26(47-16)33-6-5-12(14(7-33)24(29)40)13-3-1-2-4-15(13)35/h5-7,10-11,13,16-17,19-22,26-27,36-39H,1-4,8-9H2,(H5-,28,29,30,31,40,41,42,43,44)/t13-,16-,17-,19-,20-,21+,22+,26+,27+/m0/s1
• InChIKey: HTFHWJHTWKCYLR-RMBGOBTOSA-N

名称和登记号

名称

• IUPAC标准名: 1-[(2R,3R,4R,5S)-5-({[(S)-({[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-3-carbamoyl-4-[(1S)-2-oxocyclohexyl]-1$l^{5}-pyridin-1-ylium
• IUPAC传统名: 1-[(2R,3R,4R,5S)-5-({[(S)-([(2S,3R,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy(hydroxy)phosphoryl phosphonato)]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-3-carbamoyl-4-[(1S)-2-oxocyclohexyl]-1$l^{5}-pyridin-1-ylium
• 别名: Nicotinamide Adenine Dinucleotide Cyclohexanone

登记号

• PubChem SID: 160966314; 46508568
• PubChem CID: 46936590

理论计算性质

JChem

• Acid pKa: -7.028098
• 质子受体: 16
• 质子供体: 7
• LogD (pH = 5.5): -9.958359
• LogD (pH = 7.4): -10.215322
• Log P: -9.269678
• 摩尔折射率: 167.7341 cm^3
• 极化性: 66.50446 Å^3
• 极化表面积: 338.16 Å^2
• 可自由旋转的化学键: 12
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: -0.64
• LOG S: -2.68
• 溶解度: 1.71e+00 g/l

详细说明

DrugBank - DB03168

Drug information: experimental